Open AccessPegylated Long-Acting Human Growth Hormone Is Well-Tolerated in Healthy Subjects and Possesses a Potential Once-Weekly Pharmacokinetic and Pharmacodynamic Treatment Profile
Author(s) -
Michael Højby Rasmussen,
Britta Væver Bysted,
Thomas W. Anderson,
Thomas Klitgaard,
Jesper Madsen
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-2813
Subject(s) - pharmacokinetics , pharmacodynamics , pharmacology , medicine , human growth hormone , recombinant dna , growth hormone , hormone , chemistry , biochemistry , gene
Recombinant human GH (rhGH) is usually administered as a daily sc injection, which may be both inconvenient and distressing for patients. NNC126-0083 is a pegylated rhGH developed with the aim of reducing serum clearance and thereby prolonging the exposure leading to once-weekly sc administration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom